Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 9:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–20 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Low-Risk, Early Stage Breast Cancer Clear all
Recruiting Not applicable Interventional

Post-Marketing Study for Early-Stage Low-Risk Breast Cancer Treatment Using ProSense® Cryoablation (ChoICE Trial)

NCT07629206
View directory record Official record
Conditions
Low-Risk, Early Stage Breast Cancer
Interventions
Cryoablation
Device
Lead sponsor
IceCure Medical Ltd.
Industry
Eligibility
70 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
2
States / cities
Glendale, California • Germantown, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 12, 2026, 9:39 PM EDT
Completed Phase 4 Interventional

Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer

NCT00082277
View directory record Official record
Conditions
Breast Cancer
Interventions
Anastrozole, Risedronate Sodium
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
55 Years and older · Female only
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
8
States / cities
Palm Springs, California • Jacksonville, Florida • New Orleans, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2011 · Synced Sep 12, 2026, 9:39 PM EDT
Suspended Phase 3 Interventional

Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam Trial

NCT06671912
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, HER2-Negative Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
Interventions
Anastrozole, Letrozole, Exemestane, Tamoxifen, Mammogram, Magnetic Resonance Imaging, Dual X-ray Absorptiometry, Biospecimen Collection, Questionnaire Administration
Drug · Procedure · Biological + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1,556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
728
States / cities
Anchorage, Alaska • Gilbert, Arizona • Goodyear, Arizona + 559 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 12, 2026, 9:39 PM EDT
Active, not recruiting Phase 1 Interventional

Focused Ultrasound and Gemcitabine in Breast Cancer

NCT04796220
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms
Interventions
Focused Ultrasound, Gemcitabine and Focused Ultrasound
Device · Other
Lead sponsor
Patrick Dillon, MD
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 12, 2026, 9:39 PM EDT
Recruiting Not applicable Interventional

Optimization of Cardiac Imaging in Women With Early-Stage Breast Cancer

NCT07630402
View directory record Official record
Conditions
Breast Cancer With Low to Intermediate HER2 Expression
Interventions
Echocardiogram
Procedure
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 79 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 12, 2026, 9:39 PM EDT
Recruiting Phase 3 Interventional

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

NCT06966700
View directory record Official record
Conditions
Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
Interventions
Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication, Carboplatin, Paclitaxel, Doxorubicin, Epirubicin, Cyclophosphamide, Capecitabine, Olaparib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
2,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
63
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 12, 2026, 9:39 PM EDT
Active, not recruiting Not applicable Interventional

Partial Breast Proton Therapy for Early Stage Breast Cancer

NCT01310530
View directory record Official record
Conditions
Breast Cancer
Interventions
Proton Beam Radiotherapy
Radiation
Lead sponsor
Loma Linda University
Other
Eligibility
40 Years to 80 Years · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
2
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 12, 2026, 9:39 PM EDT
Completed Phase 3 Interventional Results available

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

NCT00538850
View directory record Official record
Conditions
Cancer
Interventions
Fentanyl sublingual spray, Placebo
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Chandler, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Sep 12, 2026, 9:39 PM EDT
Completed Not applicable Interventional

Avoiding Low-value Treatments in Older Women With Early-stage Breast Cancer: Piloting a Patient Decision Aid

NCT05140252
View directory record Official record
Conditions
Breast Cancer
Interventions
Breast cancer decision aid
Behavioral
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
70 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Sep 12, 2026, 9:39 PM EDT
Active, not recruiting No phase listed Observational

IORT-Breast at Medical Center Navicent Health

NCT04595435
View directory record Official record
Conditions
Breast Cancer Female, Early-stage Breast Cancer
Interventions
Lumpectomy, Intraoperative Radiation Therapy
Procedure · Radiation
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
55 Years and older · Female only
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2033
U.S. locations
1
States / cities
Macon, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 12, 2026, 9:39 PM EDT
Recruiting Phase 1 Interventional

DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer

NCT05504707
View directory record Official record
Conditions
Triple Negative Breast Cancer, HER2-negative Breast Cancer
Interventions
HER2 - primed Dendritic cells, HER3 - primed Dendritic cells
Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 12, 2026, 9:39 PM EDT
Recruiting Phase 2 Interventional

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

NCT04553770
View directory record Official record
Conditions
Early-stage Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Invasive Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer
Interventions
Anastrozole, Therapeutic Conventional Surgery, Trastuzumab Deruxtecan
Drug · Procedure · Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
9
States / cities
Fullerton, California • Los Alamitos, California • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Sep 12, 2026, 9:39 PM EDT
Completed No phase listed Observational

Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer

NCT00897793
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Prostate Cancer
Interventions
venipuncture, radiation therapy
Procedure · Radiation
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 11, 2013 · Synced Sep 12, 2026, 9:39 PM EDT
Recruiting Phase 3 Interventional

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

NCT06492616
View directory record Official record
Conditions
Breast Cancer
Interventions
Elacestrant, Anastrozole, Letrozole, Exemestane, Tamoxifen
Drug
Lead sponsor
Stemline Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4,220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
174
States / cities
Daphne, Alabama • Chandler, Arizona • Gilbert, Arizona + 137 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 12, 2026, 9:39 PM EDT
Completed Not applicable Interventional

Effect of Low Intensity Vibration (LIV) on Aromatase Inhibitor- Induced Musculoskeletal Dysfunction in Early Stage Breast Cancer Survivors

NCT03712813
View directory record Official record
Conditions
Breast Cancer
Interventions
Macrodyne LivMD plate
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 12, 2026, 9:39 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Family Quality of Life Among Families With a Member Who is a Cancer Patient

NCT00544336
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Prostate Cancer, Solid Tumor
Interventions
questionnaire administration, survey administration, quality-of-life assessment
Other · Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
21 Years and older
Enrollment
366 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 9, 2012 · Synced Sep 12, 2026, 9:39 PM EDT
Terminated Phase 2 Interventional Results available

Study of Stereotactic Radiotherapy for Breast Cancer

NCT03043794
View directory record Official record
Conditions
Breast Cancer
Interventions
Stereotactic Body Radiation Therapy SBRT
Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
50 Years to 100 Years · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 12, 2026, 9:39 PM EDT
Recruiting Phase 2 Interventional

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

NCT06797635
View directory record Official record
Conditions
Breast Neoplasms, Breast Cancer
Interventions
Patritumab deruxtecan, Pembrolizumab, Paclitaxel, Carboplatin, Doxorubicin hydrochloride, Epirubicin hydrochloride, Cyclophosphamide, Capecitabine, Olaparib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
8
States / cities
Santa Monica, California • Skokie, Illinois • Billings, Montana + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 12, 2026, 9:39 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence

NCT01479244
View directory record Official record
Conditions
Breast Cancer With Low to Intermediate HER2 Expression
Interventions
NeuVax™ vaccine, Leukine® (sargramostim, GM-CSF) and water for injection
Biological
Lead sponsor
Galena Biopharma, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
758 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
81
States / cities
Bessemer, Alabama • Mobile, Alabama • Peoria, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2017 · Synced Sep 12, 2026, 9:39 PM EDT
Recruiting Phase 2 Interventional

BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer

NCT04891068
View directory record Official record
Conditions
Breast Cancer Invasive, Early-stage Breast Cancer, High Risk Breast Carcinoma
Interventions
Azacitidine
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 12, 2026, 9:39 PM EDT